Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Operating Leases (2019 - 2025)

KalVista Pharmaceuticals' Operating Leases history spans 6 years, with the latest figure at $4.3 million for Q2 2025.

  • On a quarterly basis, Operating Leases fell 28.01% to $4.3 million in Q2 2025 year-over-year; TTM through Apr 2025 was $4.3 million, a 28.01% decrease, with the full-year FY2025 number at $4.3 million, down 28.01% from a year prior.
  • Operating Leases hit $4.3 million in Q2 2025 for KalVista Pharmaceuticals, down from $4.4 million in the prior quarter.
  • Over the last five years, Operating Leases for KALV hit a ceiling of $7.1 million in Q2 2023 and a floor of $1.1 million in Q1 2021.
  • Historically, Operating Leases has averaged $5.2 million across 4 years, with a median of $5.0 million in 2021.
  • Biggest five-year swings in Operating Leases: surged 377.39% in 2021 and later plummeted 33.73% in 2024.
  • Tracing KALV's Operating Leases over 4 years: stood at $5.0 million in 2021, then increased by 29.73% to $6.5 million in 2023, then crashed by 32.22% to $4.4 million in 2024, then dropped by 2.41% to $4.3 million in 2025.
  • Business Quant data shows Operating Leases for KALV at $4.3 million in Q2 2025, $4.4 million in Q4 2024, and $4.3 million in Q4 2024.